Diaceutics
Diaceutics runs DXRX, a diagnostic commercialisation platform integrating real-world testing data from over 52,500 laboratories in 53 countries to support precision medicine launches.
Diaceutics provides end-to-end therapy commercialisation for precision medicine, working with pharmaceutical and biotech companies to close the gap between diagnostic testing and treatment. The company combines real-world diagnostic data, global laboratory expertise and physician engagement, and has been operating for over 20 years across 53 countries. Its stated purpose is to ensure that every eligible patient receives the right therapy at precisely the right time.
At the centre of the business is DXRX, described as the world's first diagnostic commercialisation platform. It integrates multiple pipelines of real-world diagnostic testing data drawn from a global network of laboratories, allowing pharmaceutical companies to plan and optimise the launch and commercialisation of precision medicines. The underlying data assets are substantial: more than 52,515 laboratories, 481m de-identified patient records and 453m testing event data points, refreshed weekly.
Technical work spans several domains: real-world diagnostic data integration, the construction of diagnostic testing data pipelines, analytics and data-driven insight, the DXRX platform itself, and physician engagement. The company's reach extends across oncology, rare disease, cardiology, neurology and autoimmune conditions, in addition to its core diagnostics and precision medicine markets.